Abstract: The year of 2017 marked a historic milestone for China's pharmaceutical industry. China's comprehensive drug regulatory reform has made major steps forward to fully align with international standards, preluding a new era for innovative drug R & D (drug innovation 2.0). Based on many rounds of brainstorming, distillation of experts' insights and persistence on reality and foresight, Shanghai Center for iDrug Discovery and Development (SCiDDD) recently held think-tank roundtable conference and issued this 2018 Outlook with important reference value for China's development trends in drug R & D, regulation and policy.